Brief: Vivoryon Reports Positive Outcome To Proceed With Alzheimer Drug Study
23/10/2023 07:45
Oct 23 (Reuters) - Vivoryon Therapeutics NV 05Y.F :
* VIVORYON THERAPEUTICS REPORTS POSITIVE OUTCOME FROM
INDEPENDENT
DATA SAFETY MONITORING BOARD WITH UNANIMOUS DECISION FOR
VIVA-MIND U.S. STUDY OF VAROGLUTAMSTAT IN ALZHEIMER’S DISEASE TO
PROCEED AT HIGHEST INVESTIGATED DOSE
Source text for Eikon: urn:newsml:reuters.com:*:nGNX6NnY3g
Further company coverage: 05Y.F
(Gdansk Newsroom)
((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))
Recent news on Vivoryon Therapeutics NV
See all newsEurope Research Roundup: Colonial, Covivio SA, Fluidra SA
Brief: Vivoryon Therapeutics Says VIVIAD Phase 2B Study Does Not Meet Primary Endpoints
Brief: Vivoryon Reports Positive Outcome To Proceed With Alzheimer Drug Study
Jefferies starts Vivoryon at 'buy' on positive risk/reward from Alzheimer's pill
Brief: Vivoryon Therapeutics Announces Proposed Appointment Of Frank Weber As Chief Executive Officer